52-Week Safety and Efficacy of Amlitelimab in Participants with Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis from the Open-Label Long-Term ATLANTIS Trial. J of Skin. 2026;10(3):s780. doi:10.25251/nt8d2g73